๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Long-term Follow-up Study of BRL-101 for TDT

Recruitingn/aAges 3 Years - 35 YearsAllBioray Laboratories
NCT06298630 on ClinicalTrials.gov โ†—
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s) 2. Treated with BRL-101 for therapy of transfusion-dependent ฮฒ-thalassemia. Exclusion Criteria: \- There are no exclusion criteria for this study
๐Ÿ’Š

What it tests

  • Assessments
๐Ÿ“

Where

7 sites
Nanfang Hospital, Southern Medical University
Guangzhou, China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, China
Shenzhen Children 's Hospital
Shenzhen, China
No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital
Nanning, China
Xiangya Hospital of Central South University
Changsha, China
Tianjin Institute of Hematology
Tianjin, China
The First Affiliated Hospital of GUANGXI MEDICAL UNIVERSITY
Guangxi, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy